Biopharmaceuticals

Boston – September 15, 2026 -- EMD Serono, Inc., the U.S. and Canada healthcare business of Merck KGaA, Darmstadt, Germany, has acquired two preclinical fertility drug programs from PostEra, a biotechnology company that uses artificial intelligence for small-molecule drug discovery.

EMD Serono takes over two AI-derived fertility programs from PostEra

The deal covers a class of follicle-stimulating hormone receptor (FSHR) agonists for ovarian stimulation in IVF and a separate class of luteinizing hormone/chorionic gonadotropin receptor (LHCGR) agonists targeting male infertility and ovulation triggering in IVF. Both programs were developed over the past two years using PostEra's Proton AI platform and remain in preclinical development, with safety and efficacy in humans not yet established.

Berlin – September 15, 2026 -- The European Commission is redrawing public procurement rules to treat supply security as a strategic asset, pressuring Germany to overhaul how statutory health insurers award pharmaceutical rebate contracts.

Brussels Moves to Rank Quality and Resilience Above Lowest Price

The Commission's draft directive would require public tenders to be awarded based on the best price-quality ratio rather than price alone, explicitly allowing supply security and resilience to factor into contract awards. The proposal also permits splitting large contracts into smaller lots to reduce dependency on single suppliers and diversify supply chains. For strategically sensitive procurement categories, the draft opens the door to preferential treatment for European or trade-aligned suppliers.

Berlin – – September 15, 2026 -- The European Commission today unveiled the EU Public Procurement Act (PPA), a comprehensive proposal to modernize European procurement law, drawing an immediate response from Germany's pharmaceutical industry association BPI.

BPI demands supply security as binding procurement criterion

Dr. Kai Joachimsen, Chief Executive of the BPI (Bundesverband der Pharmazeutischen Industrie), said the European Commission must make supply security a mandatory guideline for pharmaceutical procurement. He stated the goal must be supply sovereignty, achieved through strong production capacities in Europe and diversified, resilient supply chains.

Galway, Ireland – – September 13, 2026 -- Neurent Medical has secured a €25 million growth debt financing facility from Claret Capital Partners to accelerate commercial expansion of its NEUROMARK® System for chronic rhinitis treatment.

Debt facility follows €62.5 million Series C round completed earlier in 2026

The new €25 million facility builds on Neurent Medical's €62.5 million Series C financing round, which closed earlier this year. The combined capital reinforces the company's position in minimally invasive treatments for chronic inflammatory sinonasal diseases.

San Rafael, Calif. – September 13, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reported that its Phase 3 CANOPY-HCH-3 trial of VOXZOGO (vosoritide) met its primary endpoint in children with hypochondroplasia, with results published in NEJM Evidence and presented at the European Society for Paediatric Endocrinology 2026 Annual Meeting.

New York – September 13, 2026 -- Michael J. Fox, founder of The Michael J. Fox Foundation for Parkinson's Research (MJFF), has been named a laureate of the 2026 Lasker~Bloomberg Public Service Award, one of America's most prestigious biomedical research prizes. The Lasker Foundation cited Fox for "dispelling the stigma of the disease and spearheading a revolution in the world of Parkinson's research." More than 100 past Lasker Laureates have gone on to win the Nobel Prize.

San Jose, Calif. – September 13, 2026 -- Anixa Biosciences, Inc. (NASDAQ: ANIX) confirmed that Bloomberg TV will air an interview with Chairman and CEO Dr. Amit Kumar and breast cancer vaccine trial patient Sherie Steinberg this Saturday, September 12, at 7:00 PM ET, reaching an estimated 73 million U.S. homes.

Bloomberg TV segment to spotlight breast cancer vaccine data and patient outcomes

The interview will air on the RedChip Small Stocks, Big Money show and is also available online. Dr. Kumar is expected to detail recent progress in Anixa's cancer vaccine development program, including a breast cancer vaccine designed for three applications: treating existing disease, preventing recurrence, and reducing the risk of initial onset in high-risk patients.

Suzhou – September 13, 2026 -- Transcenta Therapeutics has licensed its Highly Intensified Continuous Bioprocessing (HiCB) platform to WuXi Biologics under a non-exclusive technology agreement, securing an upfront payment of RMB 10 million plus future milestone payments.

Transcenta and subsidiary HJB grant WuXi Biologics non-exclusive rights to HiCB and ExcelPro media

Under the deal, Transcenta and its subsidiary HJB will license certain technologies tied to the HiCB continuous bioprocessing platform and its ExcelPro cell culture media to WuXi Biologics and its affiliates. WuXi Biologics will become a strategic CMC development partner supporting molecules across Transcenta's pipeline.

Chino, Calif. – September 13, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.

Clinical trial confirms 16.90% reduction in glucose AUC

In a double-blind, randomized, placebo-controlled crossover trial, subjects supplemented with SlimSEBTM showed a 16.90% reduction in Area Under the Curve (AUC), a standard measure of post-prandial glycemic response. The result demonstrates statistically significant improvement in blood sugar control following meals.

Cambridge, Mass. – September 13, 2026 -- Solstice Oncology has launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, to advance a second-generation CTLA-4 antibody into earlier-stage cancer treatment.

Solstice secures $225 million to fund neoadjuvant immuno-oncology program

The clinical-stage company is focused on treating cancer in the neoadjuvant setting, before tumors have hardened resistance to therapy. Its lead candidate, porustobart, is a differentiated, Fc-enhanced CTLA-4 antibody being developed across two clinical indications, including microsatellite-stable (MSS) colon cancer and a second, undisclosed indication.